Latest Clinical Trials
Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma City of Hope Medical Center NA
SUSPENDED
(Sep 1, 2026)
PHASE1, PHASE2 Biologically Guided Radiation Therapy (BgRT) and Stereotactic Body Radiation Therapy (SBRT) to Tyrosine Kinase Inhibitor in Oligoprogressive Oncogenic Positive Non-Small Cell Lung Carcinoma City of Hope Medical Center NA
SUSPENDED
(Sep 1, 2026)
PHASE2 Zanubrutinib in Combination With Odronextamab for the Treatment of Patients With Richter's Transformation City of Hope Medical Center NA
RECRUITING
(Sep 1, 2026)
PHASE1 Zanubrutinib and Sonrotoclax for the Treatment of Relapsed Chronic Lymphocytic Leukemia /Small Lymphocytic Leukemia, ZeuS-2 Trial City of Hope Medical Center NA
NOT YET RECRUITING
(Sep 1, 2026)
PHASE2 Combination Chemotherapy With or Without Trastuzumab in Treating Patients With Stage II or Stage III Breast Cancer City of Hope Medical Center NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2 Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin Lymphoma City of Hope Medical Center NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE1, PHASE2 Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia City of Hope Medical Center NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2 Gene Therapy After Frontline Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma City of Hope Medical Center NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE1 Diffuse Optical Imaging With Indocyanine Green Solution in Imaging Pelvic Lymph Nodes in Patients With Stage II Prostate Cancer Undergoing Surgery City of Hope Medical Center NA
COMPLETED
(Aug 1, 2026)
PHASE1 Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm City of Hope Medical Center NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE1 Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed HL City of Hope Medical Center NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2 Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma City of Hope Medical Center NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2 Combination Chemotherapy, Total Body Irradiation, and Donor Blood Stem Cell Transplant in Treating Patients With Secondary Myelofibrosis City of Hope Medical Center NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE1 Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL. City of Hope Medical Center NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE1 Daratumumab After Stem Cell Transplant in Treating Patients With Multiple Myeloma City of Hope Medical Center NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2 Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma City of Hope Medical Center NA
COMPLETED
(Aug 1, 2026)
PHASE1 IRX-2, Cyclophosphamide, and Nivolumab in Treating Patients With Recurrent or Metastatic and Refractory Liver Cancer City of Hope Medical Center NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE1 Safety of Blood Stem Cell Mobilization With Plerixafor in Patients With Sickle Cell Disease City of Hope Medical Center NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE1 Total Marrow and Lymphoid Irradiation as Conditioning Regimen Before Hematopoietic Cell Transplantation in Patients With Myelodysplastic Syndrome or Acute Leukemia City of Hope Medical Center NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2 PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer City of Hope Medical Center NA
RECRUITING
(Aug 1, 2026)
PHASE1 64Cu-DOTA-pembrolizumab PET for the Study of PD1 Expression City of Hope Medical Center NA
WITHDRAWN
(Aug 1, 2026)
PHASE1 Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma City of Hope Medical Center NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2 Lenvatinib and Pembrolizumab Maintenance Therapy for the Treatment of Patients of Advanced Unresectable Pancreatic Cancer City of Hope Medical Center NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2 Modified Immune Cells (TAG72-CAR T Cells) for the Treatment of Patients With Platinum Resistant Epithelial Ovarian Cancer City of Hope Medical Center NA
RECRUITING
(Aug 1, 2026)
PHASE1 8-Chloroadenosine in Combination With Venetoclax for the Treatment of Patients With Relapsed/Refractory Acute Myeloid Leukemia City of Hope Medical Center NA
RECRUITING
(Aug 1, 2026)
PHASE1 FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer City of Hope Medical Center NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE1, PHASE2 Botensilimab, Balstilimab and Regorafenib for the Treatment of Patients With Microsatellite Stable Metastatic Colorectal Cancer Who Have Progressed on Prior Chemotherapy City of Hope Medical Center NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE1, PHASE2 CD19-Car T Cell Therapy for the Treatment of Older Adults With Acute Lymphoblastic Leukemia in First Remission City of Hope Medical Center NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE1 Lenalidomide and Epcoritamab for the Treatment of Previously Untreated Follicular Lymphoma City of Hope Medical Center NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2 Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma City of Hope Medical Center NA
RECRUITING
(Aug 1, 2026)
PHASE1 HB-adMSCs for the Treatment of Crohn's Disease Hope Biosciences Research Foundation NA
RECRUITING
(Aug 1, 2026)
PHASE2 Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT Trial City of Hope Medical Center NA
RECRUITING
(Aug 1, 2026)
PHASE2 Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial City of Hope Medical Center NA
NOT YET RECRUITING
(Aug 1, 2026)
PHASE3 Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Standard Treatment City of Hope Medical Center NA
RECRUITING
(Aug 1, 2026)
PHASE2 Duvelisib Maintenance for the Treatment of Peripheral T-Cell Lymphomas City of Hope Medical Center NA
RECRUITING
(Aug 1, 2026)
PHASE2 Ivonescimab and ADG126, Alone, and in Combination With Leucovorin and Fluorouracil or FOLFIRI Regimen for the Treatment of Microsatellite Stable Advanced/Metastatic Colorectal Cancer City of Hope Medical Center NA
NOT YET RECRUITING
(Aug 1, 2026)
PHASE1 Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma City of Hope Medical Center NA
RECRUITING
(Aug 1, 2026)
PHASE2 Locoregional Administration of Genetically Engineered Cells (EGFR/IL13Rα2 Pool-CAR T Cells) for the Treatment of Recurrent or Progressive High-Grade Gliomas City of Hope Medical Center NA
RECRUITING
(Aug 1, 2026)
PHASE1 Total Marrow and Lymphoid Irradiation in Combination With Fludarabine and Melphalan as Conditioning for Allogeneic Peripheral Blood Stem Cell Hematopoietic Cell Transplant in Older Patients With Refractory and Relapsed Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome City of Hope Medical Center NA
RECRUITING
(Aug 1, 2026)
PHASE2 A PET Imaging Agent (64Cu-DOTA-Pembrolizumab) for Determining Treatment Response Among Patients With Stage IV Non-small Cell Lung Cancer Receiving Pembrolizumab City of Hope Medical Center NA
RECRUITING
(Aug 1, 2026)
PHASE1 Genetically Engineered Cells (BAFFR-CAR T Cells) for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia and B-cell Lymphoblastic Lymphoma City of Hope Medical Center NA
NOT YET RECRUITING
(Aug 1, 2026)
PHASE1 FPS-ZM1 With or Without Dexamethasone for Controlling Post Operative Cerebral Edema in Patients With Glioblastoma City of Hope Medical Center NA
NOT YET RECRUITING
(Aug 1, 2026)
PHASE1 RNR Inhibitor COH29 in Treating Patients With Solid Tumors That Are Refractory to Standard Therapy or For Which No Standard Therapy Exists City of Hope Medical Center NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE1 Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma City of Hope Medical Center NA
RECRUITING
(Jul 1, 2026)
PHASE1, PHASE2 Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory City of Hope Medical Center NA
SUSPENDED
(Jul 1, 2026)
PHASE1 Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant City of Hope Medical Center NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE1 Leflunomide in Treating Patients With Steroid Dependent Chronic Graft Versus Host Disease City of Hope Medical Center NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE1 90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic Syndrome City of Hope Medical Center NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE1 Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination With Gemcitabine and Cisplatin for the Treatment of Biliary Tract Cancer Patients With Peritoneal Metastases City of Hope Medical Center NA
RECRUITING
(Jul 1, 2026)
PHASE1 TMLI and Alemtuzumab for Treatment of Sickle Cell Disease City of Hope Medical Center NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE1 Leflunomide in Combination With Steroids for the Treatment of Acute Graft-versus-Host Disease After Donor Stem Cell Transplant for Hematologic Malignancies City of Hope Medical Center NA
RECRUITING
(Jul 1, 2026)
PHASE1 225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome City of Hope Medical Center NA
RECRUITING
(Jul 1, 2026)
PHASE1 Tagraxofusp and Azacitidine for Maintenance Treatment in Patients With CD123 Positive AML and MDS Following Donor Hematopoietic Cell Transplant City of Hope Medical Center NA
RECRUITING
(Jul 1, 2026)
PHASE1 Denosumab for Type 1 Diabetes City of Hope Medical Center NA
RECRUITING
(Jul 1, 2026)
PHASE1, PHASE2 High Cannabidiol Plant Extract (BRC-001) to Improve Aromatase Inhibitor-Induced Arthralgia in Women With Breast Cancer City of Hope Medical Center NA
SUSPENDED
(Jul 1, 2026)
PHASE2 Papaverine in Combination With Radiation Therapy for the Treatment of Locally Advanced Rectal Cancer, DINOMITE Trial City of Hope Medical Center NA
RECRUITING
(Jul 1, 2026)
PHASE1 A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant City of Hope Medical Center NA
RECRUITING
(Jul 1, 2026)
PHASE1 Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukemia City of Hope Medical Center NA
RECRUITING
(Jul 1, 2026)
PHASE1 Belinostat in Combination With Azacitidine or Pralatrexate for the Treatment of Relapse or Refractory T-cell Lymphoma City of Hope Medical Center NA
NOT YET RECRUITING
(Jul 1, 2026)
PHASE1 Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Locally Advanced or Metastatic Breast Cancer City of Hope Medical Center NA
ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE2 Nab-Paclitaxel in Treating Older Patients With Locally Advanced or Metastatic Breast Cancer City of Hope Medical Center NA
ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE2 Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma City of Hope Medical Center NA
ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE1 Total Marrow and Lymphoid Irradiation and Chemotherapy Before DSCT in Treating Patients With High-Risk ALL or AML City of Hope Medical Center NA
ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE2 Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treating Participants With High-Risk Acute Leukemia or Myelodysplastic Syndrome City of Hope Medical Center NA
SUSPENDED
(Jun 1, 2026)
PHASE1 CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory CS1 Positive Multiple Myeloma City of Hope Medical Center NA
SUSPENDED
(Jun 1, 2026)
PHASE1 Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer City of Hope Medical Center NA
SUSPENDED
(Jun 1, 2026)
PHASE1 Imaging of Solid Tumors Using FAP-2286 Thomas Hope NA
RECRUITING
(Jun 1, 2026)
PHASE1 Acalabrutinib, Umbralisib, and Ublituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma City of Hope Medical Center NA
ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE2 CC-486 and Nivolumab for the Treatment of Hodgkin Lymphoma Refractory to PD-1 Therapy or Relapsed City of Hope Medical Center NA
ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE1 Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Hematopoietic Stem Cell Transplants City of Hope Medical Center NA
ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE2 Intracerebroventricular Administration of CD19-CAR T Cells (CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/Mem T-lymphocytes) for the Treatment of Central Nervous System Lymphoma City of Hope Medical Center NA
RECRUITING
(Jun 1, 2026)
PHASE1 Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's Transformation City of Hope Medical Center NA
ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE2 Humanized CD19-Specific CAR T Cells for the Treatment of Patients With Positive Relapsed or Refractory CD19 Positive B-Cell Acute Lymphoblastic Leukemia City of Hope Medical Center NA
SUSPENDED
(Jun 1, 2026)
PHASE1 Metformin for the Treatment of Insulin Resistance in Women With Stage I-III Breast Cancer Completing Chemotherapy City of Hope Medical Center NA
RECRUITING
(Jun 1, 2026)
PHASE3 Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas City of Hope Medical Center NA
RECRUITING
(Jun 1, 2026)
PHASE1 Fluorescence-Guided Surgical Resection for Reducing Unexpected Positive Margins in Patients With Sarcoma, SarcoSIGHT Trial City of Hope Medical Center NA
RECRUITING
(Jun 1, 2026)
PHASE2 Busulfan, Etoposide, and Total-Body Irradiation in Treating Patients Undergoing Donor Stem Cell or Bone Marrow Transplant for Advanced Hematologic Cancer City of Hope Medical Center NA
COMPLETED
(May 1, 2026)
PHASE2 Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders City of Hope Medical Center NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE2 Hormone Therapy and Intensity-Modulated Radiation Therapy in Treating Patients With Metastatic Prostate Cancer City of Hope Medical Center NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE2 Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients of Different Ages With Metastatic Breast Cancer City of Hope Medical Center NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE2 Carmustine, Etoposide, Cyclophosphamide, and Stem Cell Transplant in Treating Patients With HIV-Associated Lymphoma City of Hope Medical Center NA
COMPLETED
(May 1, 2026)
PHASE1 Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer City of Hope Medical Center NA
COMPLETED
(May 1, 2026)
PHASE2 Haploidentical Transplantation With Pre-Transplant Immunosuppressive Therapy for Patients With Sickle Cell Disease City of Hope Medical Center NA
RECRUITING
(May 1, 2026)
PHASE1 Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas City of Hope Medical Center NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE1, PHASE2 Megestrol Acetate With or Without Pterostilbene in Treating Patients With Endometrial Cancer Undergoing Hysterectomy City of Hope Medical Center NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE2 PSCA-CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer City of Hope Medical Center NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE1 Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma City of Hope Medical Center NA
RECRUITING
(May 1, 2026)
PHASE2 Chemoradiation and Pembrolizumab Followed by Pembrolizumab and Lenvatinib Before Surgery for the Treatment of Non-metastatic Esophageal or Esophageal/Gastroesophageal Junction Cancer City of Hope Medical Center NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE2 Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lymphoblastic Leukemia City of Hope Medical Center NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE1 Tafasitamab and Zanubrutinib for the Treatment of Patients With Newly Diagnosed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, TaZA CLL Study City of Hope Medical Center NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE2 Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant City of Hope Medical Center NA
RECRUITING
(May 1, 2026)
PHASE1 A Study to Investigate the Effect of Food on the Bioavailability of Oral Paclitaxel Administered With Encequidar in Participants With Advanced Solid Tumors Health Hope Pharma NA
NOT YET RECRUITING
(May 1, 2026)
PHASE1 Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma City of Hope Medical Center NA
NOT YET RECRUITING
(May 1, 2026)
PHASE2 BSB-2002 After Cyclophosphamide and Fludarabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With NPM1 Mutation City of Hope Medical Center NA
NOT YET RECRUITING
(May 1, 2026)
PHASE1 Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas City of Hope Medical Center NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE1 Pevonedistat and Decitabine in Treating Patients With High Risk Acute Myeloid Leukemia City of Hope Medical Center NA
COMPLETED
(Apr 1, 2026)
PHASE1 Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma City of Hope Medical Center NA
RECRUITING
(Apr 1, 2026)
PHASE1, PHASE2 Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tissue Sarcoma City of Hope Medical Center NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE2 Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer. City of Hope Medical Center NA
RECRUITING
(Apr 1, 2026)
PHASE2 LB-100, Carboplatin, Etoposide, and Atezolizumab for the Treatment of Untreated Extensive-Stage Small Cell Lung Cancer City of Hope Medical Center NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE1 Acalabrutinib for the Treatment of Relapsed or Refractory Autoimmune Hemolytic Anemia in Patients With Chronic Lymphocytic Leukemia City of Hope Medical Center NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE2 68Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate Cancer Thomas Hope NA
TERMINATED
(Apr 1, 2026)
PHASE2 Copanlisib and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma City of Hope Medical Center NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE1, PHASE2 Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients City of Hope Medical Center NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE2 Navitoclax, Venetoclax, and Decitabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Previously Treated With Venetoclax City of Hope Medical Center NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE1 Enasidenib in Combination With Cobimetinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia City of Hope Medical Center NA
COMPLETED
(Apr 1, 2026)
PHASE1 Dose-Reduced Docetaxel With Cyclophosphamide for the Treatment of Vulnerable Older Women With Stage I-III HER2 Negative Breast Cancer, the DOROTHY Trial City of Hope Medical Center NA
RECRUITING
(Apr 1, 2026)
PHASE2 Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome City of Hope Medical Center NA
RECRUITING
(Apr 1, 2026)
PHASE1 Carfilzomib in Combination With Sotorasib for the Treatment of Patients With KRAS G12C Mutated Advanced or Metastatic Non-small Cell Lung Cancer City of Hope Medical Center NA
RECRUITING
(Apr 1, 2026)
PHASE1 Gemcitabine and Leflunomide in Patients With Advanced Unresectable Pancreatic Cancer City of Hope Medical Center NA
RECRUITING
(Apr 1, 2026)
PHASE1 Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma City of Hope Medical Center NA
RECRUITING
(Apr 1, 2026)
PHASE1 Testing the Addition of Pedmark to Cisplatin Chemotherapy for Reducing Drug-Induced Ear Damage in Men With Stage II-III Metastatic Testicular Germ Cell Tumors City of Hope Medical Center NA
RECRUITING
(Apr 1, 2026)
PHASE1 Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial City of Hope Medical Center NA
RECRUITING
(Apr 1, 2026)
PHASE2 Intensity-Modulated Radiation Therapy, Etoposide, and Cyclophosphamide Followed By Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia City of Hope Medical Center NA
COMPLETED
(Mar 1, 2026)
PHASE1, PHASE2 Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Triple Negative Breast Cancer City of Hope Medical Center NA
ACTIVE NOT RECRUITING
(Mar 1, 2026)
PHASE2 Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer City of Hope Medical Center NA
ACTIVE NOT RECRUITING
(Mar 1, 2026)
PHASE2 Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma City of Hope Medical Center NA
RECRUITING
(Mar 1, 2026)
PHASE2 Circulating Tumor DNA Based Minimal Residual Disease Detection for Patients With Early-Stage Breast Cancer City of Hope Medical Center NA
SUSPENDED
(Mar 1, 2026)
